- Previous Close
106.84 - Open
106.44 - Bid 106.77 x 800
- Ask 106.85 x 800
- Day's Range
105.34 - 106.92 - 52 Week Range
101.47 - 133.90 - Volume
1,186,754 - Avg. Volume
1,476,831 - Market Cap (intraday)
21.249B - Beta (5Y Monthly) 1.02
- PE Ratio (TTM)
20.37 - EPS (TTM)
5.24 - Earnings Date Feb 6, 2025 - Feb 10, 2025
- Forward Dividend & Yield 0.96 (0.90%)
- Ex-Dividend Date Sep 30, 2024
- 1y Target Est
124.38
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers robotic, surgical, and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
www.zimmerbiomet.comRecent News: ZBH
View MorePerformance Overview: ZBH
Trailing total returns as of 12/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ZBH
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ZBH
View MoreValuation Measures
Market Cap
21.25B
Enterprise Value
27.25B
Trailing P/E
20.37
Forward P/E
12.45
PEG Ratio (5yr expected)
1.40
Price/Sales (ttm)
2.90
Price/Book (mrq)
1.72
Enterprise Value/Revenue
3.59
Enterprise Value/EBITDA
12.32
Financial Highlights
Profitability and Income Statement
Profit Margin
14.27%
Return on Assets (ttm)
4.61%
Return on Equity (ttm)
8.71%
Revenue (ttm)
7.6B
Net Income Avi to Common (ttm)
1.08B
Diluted EPS (ttm)
5.24
Balance Sheet and Cash Flow
Total Cash (mrq)
569M
Total Debt/Equity (mrq)
53.61%
Levered Free Cash Flow (ttm)
1.22B